Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies
A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to $0.17. While Gilead may earn royalties on topical formulations, LEO Pharma ...
BioSpace18h
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
Gilead and LEO Pharma link on programmes for inflammatory conditions
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...
Contract Pharma20h
Gilead, LEO Pharma Partner to Accelerate Development of Oral STAT6 Program
Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...
ENDPOINTS NEWS22h
Gilead taps in­to STAT6 space via $250M deal with Leo Phar­ma
Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...